EurycomanoneCAS# 84633-29-4 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 84633-29-4 | SDF | Download SDF |
PubChem ID | 433873 | Appearance | White powder |
Formula | C20H24O9 | M.Wt | 408.4 |
Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
Synonyms | Pasakbumin A | ||
Solubility | DMSO : 16.67 mg/mL (40.82 mM; Need ultrasonic) | ||
SMILES | CC1=CC(=O)C(C2(C1CC3C45C2C(C(C(=C)C4(C(C(=O)O3)O)O)O)(OC5)O)C)O | ||
Standard InChIKey | UCUWZJWAQQRCOR-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C20H24O9/c1-7-4-10(21)13(23)17(3)9(7)5-11-18-6-28-20(27,16(17)18)12(22)8(2)19(18,26)14(24)15(25)29-11/h4,9,11-14,16,22-24,26-27H,2,5-6H2,1,3H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Eurycomanone has anti-cancer activity, it is cytotoxic on HepG2 cells by inducing apoptosis through the up-regulation of p53 and Bax, and down-regulation of Bcl-2. |
Targets | NF-kB | IkB | P450 (e.g. CYP17) | p53 | Bcl-2/Bax | Caspase | IKK |
In vitro | Eurycomanone and eurycomanol from Eurycoma longifolia Jack as regulators of signaling pathways involved in proliferation, cell death and inflammation.[Pubmed: 25230121]Molecules. 2014 Sep 16;19(9):14649-66.Eurycomanone and eurycomanol are two quassinoids from the roots of Eurycoma longifolia Jack. Eurycomanone suppresses expression of lung cancer cell tumor markers, prohibitin, annexin 1 and endoplasmic reticulum protein 28.[Pubmed: 21903368]Phytomedicine. 2012 Jan 15;19(2):138-44.Bioactive compounds from the medicinal plant, Eurycoma longifolia Jack have been shown to promote anti-proliferative effects on various cancer cell lines. |
Kinase Assay | Eurycomanone induce apoptosis in HepG2 cells via up-regulation of p53.[Pubmed: 19508737]Effect of eurycomanone on cytochrome P450 isoforms CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2E1 and CYP3A4 in vitro.[Pubmed: 23881640]J Nat Med. 2014 Apr;68(2):402-6.
Cancer Cell Int. 2009 Jun 10;9:16. Eurycomanone is a cytotoxic compound found in Eurycoma longifolia Jack. Previous studies had noted the cytotoxic effect against various cancer cell lines. The aim of this study is to investigate the cytotoxicity against human hepato carcinoma cell in vitro and the mode of action. |
Eurycomanone Dilution Calculator
Eurycomanone Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.4486 mL | 12.2429 mL | 24.4858 mL | 48.9716 mL | 61.2145 mL |
5 mM | 0.4897 mL | 2.4486 mL | 4.8972 mL | 9.7943 mL | 12.2429 mL |
10 mM | 0.2449 mL | 1.2243 mL | 2.4486 mL | 4.8972 mL | 6.1214 mL |
50 mM | 0.049 mL | 0.2449 mL | 0.4897 mL | 0.9794 mL | 1.2243 mL |
100 mM | 0.0245 mL | 0.1224 mL | 0.2449 mL | 0.4897 mL | 0.6121 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Itraconazole
Catalog No.:BCC4914
CAS No.:84625-61-6
- H-Lys(Fmoc)-OH
Catalog No.:BCC2984
CAS No.:84624-28-2
- Boc-Lys(Fmoc)-OH
Catalog No.:BCC3417
CAS No.:84624-27-1
- Fmoc-D-Val-OH
Catalog No.:BCC3573
CAS No.:84624-17-9
- Cyclogalegigenin
Catalog No.:BCN6295
CAS No.:84605-18-5
- Lorazepam
Catalog No.:BCC5970
CAS No.:846-49-1
- Boldenone
Catalog No.:BCC8892
CAS No.:846-48-0
- 5α-Androstanedione
Catalog No.:BCC8752
CAS No.:846-46-8
- Serrin A
Catalog No.:BCN6985
CAS No.:845959-98-0
- 2-Methyl-5-hydroxytryptamine hydrochloride
Catalog No.:BCC5663
CAS No.:845861-49-6
- CP 94253 hydrochloride
Catalog No.:BCC7018
CAS No.:845861-39-4
- Bakuchalcone
Catalog No.:BCN3201
CAS No.:84575-13-3
- 4-Nitrobenzyl dimethylcarbamate
Catalog No.:BCN3284
CAS No.:84640-31-3
- Tea polyphenol
Catalog No.:BCN8518
CAS No.:84650-60-2
- Decinnamoyltaxinine J
Catalog No.:BCN7210
CAS No.:84652-33-5
- Lorcaserin HCl
Catalog No.:BCC5041
CAS No.:846589-98-8
- Isoastragaloside I
Catalog No.:BCN2979
CAS No.:84676-88-0
- Astragaloside II
Catalog No.:BCN5962
CAS No.:84676-89-1
- Enalaprilat Dihydrate
Catalog No.:BCC5009
CAS No.:84680-54-6
- 3-O-(2'E,4'Z-Decadienoyl)ingenol
Catalog No.:BCN3767
CAS No.:84680-59-1
- Astragaloside I
Catalog No.:BCN5961
CAS No.:84680-75-1
- Astragaloside III
Catalog No.:BCN5963
CAS No.:84687-42-3
- Astragaloside IV
Catalog No.:BCN5960
CAS No.:84687-43-4
- Arglabin
Catalog No.:BCC5299
CAS No.:84692-91-1
Eurycomanone suppresses expression of lung cancer cell tumor markers, prohibitin, annexin 1 and endoplasmic reticulum protein 28.[Pubmed:21903368]
Phytomedicine. 2012 Jan 15;19(2):138-44.
Bioactive compounds from the medicinal plant, Eurycoma longifolia Jack have been shown to promote anti-proliferative effects on various cancer cell lines. Here we examined the effects of purified Eurycomanone, a quassinoid found in Eurycoma longifolia Jack extract, on the expression of selected genes of the A549 lung cancer cells. Eurycomanone inhibited A549 lung cancer cell proliferation in a dose-dependent manner at concentrations ranging from 5 to 20 mug/ml. The concentration that inhibited 50% of cell growth (GI(50)) was 5.1 mug/ml. The anti-proliferative effects were not fully reversible following the removal of Eurycomanone, in which 30% of cell inhibition still remained (p<0.0001, T-test). At 8 mug/ml (GI(70)), Eurycomanone suppressed anchorage-independent growth of A549 cells by >25% (p<0.05, T-test, n=8) as determined using soft agar colony formation assay. Cisplatin, a chemotherapy drug used for the treatment of non small cell lung cancer on the other hand, inhibited A549 cells proliferation at concentrations ranging from 0.2 mug/ml to 15 mug/ml with a GI(50) of 0.58 mug/ml. The treatment with Eurycomanone reduced the abundance expression of the lung cancer markers, heterogeneous nuclear ribonucleoprotein (hnRNP) A2/B1, p53 tumor suppressor protein and other cancer-associated genes including prohibitin (PHB), annexin 1 (ANX1) and endoplasmic reticulum protein 28 (ERp28) but not the house keeping genes. The mRNA expressions of all genes with the exception of PHB were significantly downregulated, 72 h after treatment (p<0.05, T-test, n=9). These findings suggest that Eurycomanone at viable therapeutic concentrations of 5-20 mug/ml exhibited significant anti-proliferative and anti-clonogenic cell growth effects on A549 lung cancer cells. The treatment also resulted in suppression of the lung cancer cell tumor markers and several known cancer cell growth-associated genes.
Eurycomanone induce apoptosis in HepG2 cells via up-regulation of p53.[Pubmed:19508737]
Cancer Cell Int. 2009 Jun 10;9:16.
BACKGROUND: Eurycomanone is a cytotoxic compound found in Eurycoma longifolia Jack. Previous studies had noted the cytotoxic effect against various cancer cell lines. The aim of this study is to investigate the cytotoxicity against human hepato carcinoma cell in vitro and the mode of action. The cytotoxicity of Eurycomanone was evaluated using MTT assay and the mode of cell death was detected by Hoechst 33258 nuclear staining and flow cytometry with Annexin-V/propidium iodide double staining. The protein expression Bax, Bcl-2, p53 and cytochrome C were studied by flow cytometry using a spesific antibody conjugated fluorescent dye to confirm the up-regulation of p53 and Bax in cancer cells. RESULTS: The findings suggested that Eurycomanone was cytotoxic on cancerous liver cell, HepG2 and less toxic on normal cells Chang's liver and WLR-68. Furthermore, various methods proved that apoptosis was the mode of death in Eurycomanone-treated HepG2 cells. The characteristics of apoptosis including chromatin condensation, DNA fragmentation and apoptotic bodies were found following Eurycomanone treatment. This study also found that apoptotic process triggered by Eurycomanone involved the up-regulation of p53 tumor suppressor protein. The up-regulation of p53 was followed by the increasing of pro-apoptotic Bax and decreasing of anti-apoptotic Bcl-2. The increased of cytochrome C levels in cytosol also results in induction of apoptosis. CONCLUSION: The data suggest that Eurycomanone was cytotoxic on HepG2 cells by inducing apoptosis through the up-regulation of p53 and Bax, and down-regulation of Bcl-2.
Eurycomanone and eurycomanol from Eurycoma longifolia Jack as regulators of signaling pathways involved in proliferation, cell death and inflammation.[Pubmed:25230121]
Molecules. 2014 Sep 16;19(9):14649-66.
Eurycomanone and eurycomanol are two quassinoids from the roots of Eurycoma longifolia Jack. The aim of this study was to assess the bioactivity of these compounds in Jurkat and K562 human leukemia cell models compared to peripheral blood mononuclear cells from healthy donors. Both Eurycomanone and eurycomanol inhibited Jurkat and K562 cell viability and proliferation without affecting healthy cells. Interestingly, Eurycomanone inhibited NF-kappaB signaling through inhibition of IkappaBalpha phosphorylation and upstream mitogen activated protein kinase (MAPK) signaling, but not eurycomanol. In conclusion, both quassinoids present differential toxicity towards leukemia cells, and the presence of the alpha,beta-unsaturated ketone in Eurycomanone could be prerequisite for the NF-kappaB inhibition.
Effect of eurycomanone on cytochrome P450 isoforms CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2E1 and CYP3A4 in vitro.[Pubmed:23881640]
J Nat Med. 2014 Apr;68(2):402-6.
Eurycomanone, an active constituent isolated from Eurycoma longifolia Jack, was examined for modulatory effects on cytochrome P450 (CYP) isoforms CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2E1 and CYP3A4 using in vitro assays. The IC50 value was determined to assess the potencies of modulation for each CYP isoform. Our results indicated that Eurycomanone did not potently inhibit any of the CYP isoforms investigated, with IC50 values greater than 250 mug/ml. Hence there appears to be little likelihood of drug-herb interaction between Eurycomanone or herbal products with high content of this compound and CYP drug substrates via CYP inhibition.